OnKure Therapeutics Reports $59.5 Million Net Loss for 2025, Faces Funding Challenges

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, reported a net loss of $59.5 million for the year ended December 31, 2025, compared to a net loss of $52.7 million for the previous year. The company, which focuses on precision medicines for cancers and other underserved diseases, has not generated any revenue from product sales and anticipates continuing to incur significant operating losses for the foreseeable future. As of December 31, 2025, OnKure had an accumulated deficit of $214.2 million and cash and cash equivalents of $59.1 million. Management believes that the current cash and cash equivalents will be sufficient to fund operations into the fourth quarter of 2026.

The increase in net loss was primarily driven by higher operating expenses. Research and development expenses rose to $48.3 million in 2025 from $43.8 million in 2024, mainly due to increased personnel-related costs, including share-based compensation, and higher clinical trial expenses. General and administrative expenses also increased to $14.7 million from $10.6 million, primarily due to increased personnel costs and professional service fees, partially offset by a decrease in legal costs. These increases were offset by an increase in interest income due to an increase in cash and cash equivalents available to invest during the year ended December 31, 2025 and decreased interest expense related to convertible notes payable issued in 2024.

OnKure's lead product candidate, OKI-219, is currently in a Phase 1 clinical trial. The company is also actively pursuing multiple additional discovery programs targeting mutations of PI3Kα. The company expects to announce a pan-mutant development candidate in the first quarter of 2026 targeting the most common PI3Kα mutations (i.e., H1047R, E545K, and E542K) in breast cancer. Additionally, they have initiated a discovery program in vascular malformations, where mutations in the PI3Kα pathway have been implicated. As of March 11, 2026, OnKure had 45 employees, with 34 dedicated to research and development activities.

The company's future success depends on several factors, including the successful clinical development and commercialization of OKI-219, obtaining regulatory approvals, establishing manufacturing and commercial capabilities, and securing adequate reimbursement for its products. OnKure anticipates that it will need to raise substantial additional capital to fund its operations and development programs. However, the company's ability to secure additional funding is uncertain, and failure to do so could force it to delay, reduce, or eliminate its product development and clinical programs.

OnKure's management has expressed substantial doubt about the company's ability to continue as a going concern, citing the need for additional capital and the uncertainties surrounding its ability to raise such funding. The company's financial statements do not include any adjustments that might result from the outcome of this uncertainty.